<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152565</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-1602</org_study_id>
    <secondary_id>2016-003838-24</secondary_id>
    <nct_id>NCT03152565</nct_id>
  </id_info>
  <brief_title>Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>AVEVAC</acronym>
  <official_title>A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm Phase I/II multicentric open labeled, with translational sub-study, of avelumab
      plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS)
      metastatic colorectal cancer patients..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2-phases study will first evaluate two different doses/schema of avelumab plus
      autologous dendritic cell vaccine (ADC) vaccines, in intention to define which dose is
      effective without hampering safety. Second phase will consist in an standard analysis of
      efficacy and progression free survival. It is expected that 4 Spanish Sites will include
      patients in phase I and 8 Spanish Centers will include patients in the phase II of the study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of Avelumab in combination with Autologous Dendritic Cells</measure>
    <time_frame>18 months</time_frame>
    <description>Dose of avelumab at which no dose limiting toxicity is shown.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients without progression of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency, nature and number of patients developing adverse events throughout follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Consensus Molecular Subtypes' (CMS) classification of Immunophenotype signature in tumor biopsies before and during treatment.</measure>
    <time_frame>18 months</time_frame>
    <description>Modified CMS classification by NanoString</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotype signature in tumor biopsies before and during treatment.</measure>
    <time_frame>18 months</time_frame>
    <description>MSS, RAS and BRAF mutation status at baseline and during treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Avelumab in combination ADC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.
Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Avelumab in combination ADC vaccine</arm_group_label>
    <other_name>Autologous Dendritic Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent of approved by the investigator's Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial
             activities.

          -  Histological diagnosis of MSS colorectal adenocarcinoma.

          -  Metastatic disease treated with at least two chemotherapy line, with or without
             targeted therapies.

          -  Male or female subjects aged ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
             criteria.

          -  Lactate dehydrogenase (LDH) levels (&lt;1.5 ULN) (between 250-450 U/L). Maximum allowed
             675 U/L.

          -  Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit
             of normality (ULN) and Aspartate Aminotransferase (AST) and Alanine Aminotransferase
             (ALT) levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented
             metastatic disease to the liver).

          -  Negative serum pregnancy test at screening for women of childbearing potential.

          -  Highly effective contraception for both male and female subjects throughout the study
             and for at least 60 days after last avelumab treatment administration if the risk of
             conception exists.

          -  Adequate hematological function: a) Haemoglobin ≥ 9 g/dL (may have been transfused).

             b) Platelet count ≥ 100 × 109/L. c) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.

          -  Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault
             formula (or local institutional standard method).

          -  Female subjects must either be of non-reproductive potential (ie, post-menopausal by
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

        Exclusion Criteria:

          -  Subjects with brain metastases.

          -  Prior organ transplantation, including allogeneic stem-cell transplantation.

          -  Presence of clinical ascites.

          -  Modified Charlson score &gt;2 (excluded cancer).

          -  Significant acute or chronic infections including, among others: Known history of
             testing positive test for human immunodeficiency virus (HIV) or known acquired
             immunodeficiency syndrome (AIDS). Positive test for Hepatitis C Virus (HCV) surface
             antigen and / or confirmatory Hepatitis C Virus (HCV) Ribonucleic acid (RNA) (if
             anti-HCV antibody tested positive).

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent: a)Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid
             disease not requiring immunosuppressive treatment are eligible. b) Subjects requiring
             hormone replacement with corticosteroids are eligible if the steroids are administered
             only for the purpose of hormonal replacement and at doses ≤ 10 mg/24 h of prednisone
             or equivalent. c) Administration of steroids through a route known to result in a
             minimal systemic exposure (topical, intranasal, intraocular, or inhalation) are
             acceptable.

          -  Local positive serologic determination to: Hepatitis B surface antigen (HBsAg),
             hepatitis B surface antibody (Anti-HBc), Hepatitis B Virus (HBV), Hepatitis C Virus
             (HCV), HCV ribonucleic acid test (HCV RNA), HIV-I RNA, Agp24 III-V + Carbonic
             anhydrase III-V (CAIII-V) ½ (MLIA) serum, Immunoglobulin G (Ig) antigen core HBV,
             reaginic antibodies (RPR) for Systemic Erythematosus Lupus (SEL-RPR) serum,
             immunoglobulin G (IgG), cytomegalovirus (EIA), Anti-Human T-Cell Lymphotropic I/II
             Viruses (HTLV) Antigens (if patient came from endemic zone), Anti-Trypanosoma Cruzi
             antibodies, Chagas (if patient came from endemic zone), when RPR positive or doubtful
             for confirmation: IgG Treponema pallidum (ELISA), Immunoglobulin M (IgM) Treponema
             pallidum (ELISA), when IgG T. Pallidum doubtful: Pt confirmatory IgG/IgM, Treponema
             pallidum (LIA).

          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 according
             National Cancer Institute-Common Terminology for Common Adverse Events/NCI-CTCAE v
             4.03), - any history of anaphylaxis, or uncontrolled asthma. Persisting toxicity
             related to prior therapy of Grade &gt;1 NCI-CTCAE v 4.03; however, alopecia and sensory
             neuropathy Grade ≤ 2 is acceptable.

          -  Pregnancy or lactation.

          -  Known alcohol or drug abuse.

          -  All other significant diseases (for example, inflammatory bowel disease, uncontrolled
             asthma), which, in the opinion of the Investigator, might impair the subject's
             tolerance of trial treatment

          -  Any psychiatric condition that would impede the understanding of informed consent

          -  Vaccination other study treatment is prohibited, within 4 weeks of the first dose of
             avelumab and while on trial.

          -  History of other tumors in the past 5 years.

          -  Active infections.

          -  Current immunosuppressive treatment, except for the following: a. intranasal, inhaled,
             topical steroids, or local steroid injection (e.g., intra-articular injection); b.
             Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;
             c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan
             premedication).&quot;

          -  Known hypersensitivity to avelumab, ADC vaccines or their components.

          -  Legal incapacity or limited legal capacity.

          -  Patients with pneumonitis and pulmonary fibrosis.

          -  Patients with cardiac medical history: Clinically significant (i.e., active)
             cardiovascular disease: cerebral vascular accident/stroke (&lt; 6 months prior to
             enrollment), myocardial infarction (&lt; 6 months prior to enrollment), unstable angina,
             congestive heart failure (≥ New York Heart Association Classification Class II), or
             serious cardiac arrhythmia requiring medication.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ highly effective birth control
             from screening to 180 days after the last dose of ADC + avelumab combination therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Maurel Santasusana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Maurel Santasusana, M.D.</last_name>
    <phone>+34 932275400</phone>
    <phone_ext>4615</phone_ext>
    <email>JMAUREL@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federico Nepote</last_name>
    <email>investigacion@mfar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Maurel Santasusana, M.D.</last_name>
      <email>JMAUREL@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Joan Maurel Santasusana, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Élez Fernández, M.D.</last_name>
      <phone>+34 93 274 60 00</phone>
      <phone_ext>6988</phone_ext>
      <email>meelez@vhio.net</email>
    </contact>
    <contact_backup>
      <last_name>Guillem Argilés</last_name>
      <phone>+34 93 274 60 00</phone>
      <phone_ext>6988</phone_ext>
      <email>gargiles@vhio.net</email>
    </contact_backup>
    <investigator>
      <last_name>Guillem Argilés, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Élez Fernández, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncológía L'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramón Salazar Soler, M.D.</last_name>
      <phone>93 260 78 22</phone>
      <email>ramonsalazar@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Ramón Salazar Soler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nuria Rodríguez Salas, M.D.</last_name>
      <phone>+34 912 071 138</phone>
      <email>nuria.rodriguez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Nuria Rodríguez Salas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana I. Ruiz Casado, M.D.</last_name>
      <phone>+34 911 91 600</phone>
      <email>arcasado@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Lourdes Gutierrez, M.D.</last_name>
      <phone>+34 911 91 600</phone>
      <email>gutinina@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ana I. Ruiz Casado, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lourdes Gutierrez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Aparicio Urtasun, M.D.</last_name>
      <phone>+34 961973139</phone>
      <email>japariciou@seom.org</email>
    </contact>
    <contact_backup>
      <last_name>David Lorente, M.D.</last_name>
      <phone>+34 961973139</phone>
      <email>dlorenteestelles@seom.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Aparicio Urtasun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lorente, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Fernández Martos, M.D.</last_name>
      <phone>+34 96 111 40 42</phone>
      <email>cfmartos@fivo.org</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Yaya Tur, M.D.</last_name>
      <phone>+34 96 111 40 42</phone>
      <email>ryayatur@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Fernández Martos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Yaya Tur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicente Alonso Orduña, M.D.</last_name>
      <phone>+34 976765500</phone>
      <phone_ext>825</phone_ext>
      <email>valonsoo@salud.aragon.es</email>
    </contact>
    <contact_backup>
      <last_name>Ana Herrero, M.D.</last_name>
      <phone>+34 976765500</phone>
      <phone_ext>825</phone_ext>
      <email>herreroa@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Vicente Alonso Orduña, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Herrero, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Polo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pilar Escudero Emperador, M.D.</last_name>
      <phone>+34 976750476</phone>
      <email>pescudero@salud.aragon.es</email>
    </contact>
    <contact_backup>
      <last_name>Alfonso Yubero Esteban, M.D.</last_name>
      <phone>+34 976750476</phone>
      <email>ayubero@salud.aragon.es</email>
    </contact_backup>
    <investigator>
      <last_name>Pilar Escudero Emperador, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfonso Yubero Esteban, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

